title: Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.
abstract: Alzheimer's disease is characterized by pathological aggregation of protein tau and amyloid-β peptides, both of which are considered to be toxic to neurons. Naturally occurring dietary flavonoids have received considerable attention as alternative candidates for Alzheimer's therapy taking into account their antiamyloidogenic, antioxidative, and anti-inflammatory properties. Experimental evidence supports the hypothesis that certain flavonoids may protect against Alzheimer's disease in part by interfering with the generation and assembly of amyloid-β peptides into neurotoxic oligomeric aggregates and also by reducing tau aggregation. Several mechanisms have been proposed for the ability of flavonoids to prevent the onset or to slow the progression of the disease. Some mechanisms include their interaction with important signaling pathways in the brain like the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways that regulate prosurvival transcription factors and gene expression. Other processes include the disruption of amyloid-β aggregation and alterations in amyloid precursor protein processing through the inhibition of β-secretase and/or activation of α-secretase, and inhibiting cyclin-dependent kinase-5 and glycogen synthase kinase-3β activation, preventing abnormal tau phosphorylation. The interaction of flavonoids with different signaling pathways put forward their therapeutic potential to prevent the onset and progression of Alzheimer's disease and to promote cognitive performance. Nevertheless, further studies are needed to give additional insight into the specific mechanisms by which flavonoids exert their potential neuroprotective actions in the brain of Alzheimer's disease patients.
authors: Laboratory of Neurosciences, Centre for Cell Biology, Health Sciences Department and Biology Department, University of Aveiro , 3810-193 Aveiro, Portugal.
authors: Filipa I
authors: FI
authors: Baptista
authors: Ana G
authors: AG
authors: Henriques
authors: Artur M S
authors: AM
authors: Silva
authors: Jens
authors: J
authors: Wiltfang
authors: Odete A B
authors: OA
authors: da Cruz e Silva
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases / Q000187:drug effects; D016229:Amyloid beta-Peptides / Q000187:drug effects; D016564:Amyloid beta-Protein Precursor / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology*; D038362:Glycogen Synthase Kinase 3 / Q000187:drug effects; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects; D058539:Phosphatidylinositol 3-Kinase / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D016875:tau Proteins / Q000187:drug effects
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D005419:Flavonoids; D016875:tau Proteins; D058539:Phosphatidylinositol 3-Kinase; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D017346:Protein Serine-Threonine Kinases; C114482:CDKL5 protein, human; D020928:Mitogen-Activated Protein Kinases; D038362:Glycogen Synthase Kinase 3; D053829:Amyloid Precursor Protein Secretases